Form 4: West Pharma SVP Reports RSU Vesting and Stock Sale

Rodolphe Jean Poussot, SVP of Strategy & Corporate Development at West Pharmaceutical Services, reported the conversion of restricted stock units into common stock and a subsequent sale for tax obligations.

Summary

• Rodolphe Jean Poussot, SVP, Strategy & Corporate Dev at West Pharmaceutical Services Inc. (WST), reported transactions involving common stock and restricted stock units (RSUs).
• On February 18, 2026, 82.299 restricted stock units converted into an equal number of common shares.
• Concurrently, 27.809 shares of common stock were disposed of at a price of $248.26 per share, likely to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Mr. Poussot beneficially owns 307.398 shares of common stock and 247.899 restricted stock units.
• The original grant of 329 restricted stock units occurred on February 18, 2025, vesting in four equal annual installments, plus dividend equivalents.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine, pre-scheduled insider transaction related to executive compensation rather than a reflection of new company performance or strategic shifts.

Positives

• The vesting of restricted stock units indicates continued compensation and alignment of interests between the executive and shareholders.
• The acquisition of common stock through RSU conversion increases the executive's direct equity stake in the company.

Negatives

• A portion of the acquired common stock (27.809 shares) was immediately disposed of to satisfy tax withholding obligations, reducing the net increase in direct beneficial ownership.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into executive stock ownership changes. These routine transactions, often pre-planned under Rule 10b5-1, are common across all industries for executives receiving equity compensation.

Stakeholder Impact

• Shareholders: Provides transparency regarding executive stock ownership and compensation, which is generally viewed positively for corporate governance.
• Employees: Reflects standard executive compensation practices, which can influence broader employee incentive structures.

Next Steps

• Future vesting installments of the remaining 247.899 restricted stock units will occur in equal annual installments, as the original grant vests over four years.

Key Dates

Keywords

West Pharmaceutical Services, WST, Insider Transaction, Form 4, Restricted Stock Units, RSU Vesting, Common Stock, Executive Compensation, Stock Sale